The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Epicypher sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
Epicypher is a biotechnology company that develops and manufactures novel products and tools for epigenetics and chromatin biology research. It develops innovative tools and technologies for studying epigenetics. Through its proprietary platform, the company offers a range of products and services, including histone modification assays, DNA methylation analysis, and chromatin interaction studies. It leverages dNuc technology for a range of applications, including SNAP-ChIP Spike-in Controls, EpiDyne substrates, and dCypher assays. The company also offers a suite of recombinant histone-binding proteins, enzymes, antibodies, and custom assay development services to complement these platforms. EpiCypher is headquartered in Durham, North Carolina, the US.
The key metrics of Epicypher related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As Epicypher is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Epicypher.
For a detailed understanding of the performance of Epicypher, buy the report here.